Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director and CEO: Gyo Sagara; “ONO”) today announced that ONO received an approval for KYPROLIS® (Generic name: carfilzomib) for Intravenous Injection 10 mg and 40 mg (“Kyprolis”), a proteasome inhibitor, in Japan for additional dosage and administration in patients with relapsed or refractory multiple myeloma, for a partial change in approved items of the manufacturing and marketing approval.
This additional approval is based on the result from a global multiple-center, randomized, openlabel Phase 3 study (ONO-7057-06/A.R.R.O.W. study), evaluating the efficacy and safety of Kyprolis in combination with dexamethasone, comparing Kyprolis 20/70 mg/m2 once-weekly dosing regimen (Kd70) versus Kyprolis 20/27 mg/m2 twice-weekly regimen (Kd27) in patients with relapsed or refractory multiple myeloma. In the result of interim analysis of progression-free survival (PFS), a primary endpoint, the median PFS was 11.2 months in the Kd70 arm versus 7.6 months in the Kd27 arm, demonstrating a statistically significant improvement (Hazard ratio: 0.69; 95% confidence interval: 0.54 - 0.88). The most frequently reported adverse events (≥20%) reported in either treatment regimen were anemia, diarrhea, fatigue, hypertension, insomnia and pyrexia.
The supplemental approval allows Kyprolis to expand its dosage and administration in combination with dexamethasone at a dosage of 20 mg/m2 only on Day 1 in Cycle 1, then escalating to 70 mg/m2 once-weekly thereafter. Kyprolis has been required so far to be administered twice-weekly under the previously approved dosage and administration, but the additional approval allows Kyprolis to be administered once-weekly leading to superior convenience.
Multiple myeloma is a blood cancer caused by an abnormality of plasma cells in the bone marrow. It is reported that there are nearly 25,000 patients* in Japan. Several treatments for multiple myeloma are currently available to patients; however, the disease relapses and progresses and eventually becomes no longer responding to therapies, also known as refractory disease. Additionally, adverse drug reactions and complications have been reported following long-term treatment, making continued treatment a challenge. The development of new therapeutic options for multiple myeloma is expected.
*: Vital Statistics and Patients Survey, 2017 (Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare).
Kyprolis is a highly selective proteasome inhibitor. Proteasome, an intra-cellular enzyme complex, functions to mediate degradation of polyubiquitinated proteins and control proliferation and differentiation of cells, as well as functional cell-death. Kyprolis inhibits certain proteasome activity, thereby inducing functional cell-death of myeloma.
In September 2010, ONO entered into a license agreement with US-based Onyx Pharmaceuticals, Inc., now an Amgen subsidiary, to exclusively develop and commercialize it for all oncology indications in Japan.
In Japan, ONO received a manufacturing and marketing approval of Kyprolis for the treatment of relapsed or refractory multiple myeloma in July 2016, in combination with lenalidomide and dexamethasone and launched it in August 2016. Kyprolis was approved for additional dosage and administration in combination with dexamethasone at a dosage of 20 mg/m2 only on Day 1 and 2 in Cycle 1, then escalating to 56 mg/m2 twice-weekly thereafter.
To read more Press Release articles, click here.